N/A N=20 Cerebral Edema in Pediatric Diabetic Ketoacidosis
Diabetic Ketoacidosis
Primary: Cerebral Edema Measured by MR Imaging (Apparent Diffusion Coefficient) — 36; 48 mm^2/sec
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=74 Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)
Diabetic Ketoacidosis
Primary: Number of Hypoglycemia Episodes After the Transition Period From Intravenous Insulin to Subcutaneous Insulin Between 2 Treatment Groups — 8; 26 number of hypoglycemia…
N/A N=75 Use of Insulin Glargine to Treat Diabetic Ketoacidosis
Diabetic Ketoacidosis
Primary: Time of Acidosis Correction
N/A N=66 Intravenous Fluids in Adults With Diabetic Ketoacidosis in the Emergency Department
Diabetic Ketoacidosis
Primary: Patient Recruitment Rate (Feasibility Outcome) — 66 Participants
Phase 3 N=1,389 Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis
Cerebral Edema · Diabetic Ketoacidosis
Primary: the Number of Participants With Glasgow Coma Score (GCS) < 14 Within the First 24 Hours of Treatment for Diabetic Ketoacidosis (DKA) — 10; 11; 11; 16 Participants — p=0.34
N/A N=28 Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises
Diabetes Mellitus, Type 2
Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml
Phase 2 N=83 IV Glucose for Dehydration Treatment
Dehydration
Primary: Measurement of Serum Ketones Before and After Administration of Intravenous Fluids for Acute Gastroenteritis — 1.10; 2.39 mmol/L — p=0.0003
N/A N=40 Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis
Diabetic Ketoacidosis
Primary: Time to Anion Gap Closure — 10.2; 11.6 hours
N/A N=43 Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
Type 1 Diabetes
Primary: Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin — 0.08; 0.25; 0.21 mM
N/A N=163 Remote Glucose Monitoring System in Hospitalized Patients With Diabetic Ketoacidosis (DKA)
Diabetic Ketoacidosis
Primary: Time to Resolution of Metabolic Acidosis — 12.84; 12.02 hours
N/A N=70 An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
Evaluate Ketogenic Stress
Primary: Change in Beta-hydroxybutyrate Levels in Blood — -0.23; 0.63; 0.24; 0.31 mM
Phase 4 N=57 Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
Diabetic Ketoacidosis · Type 1 Diabetes Mellitus
Primary: Rate of Rebound Hyperglycemia — 20; 18 Participants
N/A N=19 Exogenous Ketones in Type 2 Diabetes
Ketosis · Type 2 Diabetes
Primary: Plasma Glucose — 7.3; 7.2; 6.2; 6.6 mmol/L
Phase 4 N=48 Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment
Ketosis Prone Diabetes · Diabetes Ketoacidosis · Hyperglycemia
Primary: Length of Remission — 472; 589; 111 days
Phase 1 N=20 Ketone Pharmacokinetic Study in HFrEF
Heart Failure With Reduced Ejection Fraction
Primary: Venous pH Measured Via Peripheral Blood — 7.30; 7.28 unitless
Phase 1 N=40 Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
Heart Failure · Type 2 Diabetes Mellitus
Primary: Cardiac Output (CO) — 5.02; 4.54; 5.93; 5.10 mL/min
Phase 4 N=21 Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
Diabetes Mellitus, Type 1
Primary: Capillary Blood Beta-hydroxybutyrate (BOHB) During Outpatient Care — 0.1; 0.2 mmol/L — p=< 0.0001
Phase 2 N=20 Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
Heart Failure With Preserved Ejection Fraction
Primary: Maximal Exercise Capacity (Peak VO2) Assessed by Cardiopulmonary Exercise Testing — 1.0; 1.0 L/min
Phase 3 N=251 Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 4 N=176 Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.
Type 2 Diabetes Mellitus
Primary: Hospital Length of Stay — 2.7; 3.1 days — p=0.58
N/A N=15 Ketone Supplementation in Cystic Fibrosis
Cystic Fibrosis
Primary: Pulmonary Function Testing — 1.9; 2.0 L/sec
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Phase 4 N=85 Inpatient Diabetes on Corticosteroids
Diabetes Mellitus
Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
N/A N=1,502 Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
Diabetes Mellitus, Type 2
Primary: Number of Participants With Ketoacidosis — 1; 1 Participants
Phase 1 N=21 Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Empaglifozin · Physiological Effects of Drugs · Hypoglycemic Agents
Primary: Change in Serum β-hydroxybutyrate (BHB) — 40.717 µM — p=<0.001
N/A N=6 Very Low Carbohydrate Diet as an Adjunctive Therapy for Youth Type 1 Diabetes
Type 1 Diabetes
Primary: Percentage of Time in Target Range of 70-180 mg/dL. — 49.64; 48.86; 60.78; 50.1 percent time spent 70 mg/dL - 180 mg/dL
Phase 3 N=240 Efficacy and Safety of Dapagliflozin in Acute Heart Failure
Heart Failure · Diabetes Mellitus, Type 2
Primary: Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight — -0.31; -0.42 kg/40mg IV furosemide
Phase 2 N=599 A Phase 2b Diabetic Kidney Disease Study
Diabetic Kidney Disease
Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338
N/A N=25 Assessment of a Decision Support Tool in Participants With Type 1 Diabetes
Type 1 Diabetes
Primary: Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl — -3.8 percentage of time